ImmunoScape Targets Immunology Breakthroughs for COVID-19 & Oncology Using T-Cell Response Profiling

ImmunoScape looks deeply at what our immune system is doing, with an emphasis on the function of T cells, a key immune cell that mediates critical roles in cancer immunotherapy and conferring protection against infections. Leveraging its cutting-edge technologies and bioinformatic capabilities, ImmunoScape helps to understand the unique T cell responses in different disease settings, what targets the T cells are recognizing, and their associated properties. With these immunological insights, we partner with Biopharma and academic groups to inform the rational design of vaccines, therapeutic interventions, inform patient stratification and ultimately, improve the likelihood of clinical trial success.
In the Covid-19 space, we are partnering with Arcturus Therapeutics from San Diego to assess their COVID-19 vaccine candidate in a clinical trial with Duke NUS Singapore. ImmunoScape is also generating novel findings from COVID-19 infection studies through academic collaborations with Dr Patrick Reeves at the Massachusetts General Hospital in Boston; Dr Antonio Bertoletti of Duke-NUS in Singapore and Dr Carlo Ferrari from University of Parma, Italy.